Compare
Clene Inc. vs Lisata Therapeutics, Inc. vs Regen BioPharma Inc vs Abvc Biopharma, Inc.
| Latest fiscal year | Clene Inc. CLNN | Lisata Therapeutics, Inc. LSTA | Regen BioPharma Inc RGBP | Abvc Biopharma, Inc. ABVC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $200.0K | $170.0K | $236.6K | $296.0K |
| Revenue growth (YoY) | -41.5% | -83.0% | 0.0% | -41.9% |
| Gross margin | 78.5% (computed) | n/a | n/a | n/a |
| Operating margin | n/m | n/m | -143.1% | n/m |
| Net margin | n/m | n/m | -538.8% | n/m |
| Net income | -$26.17M | -$16.59M | -$1.27M | -$7.91M |
| EPS (Diluted) | n/a | -$1.91 | -$0.05 | -$0.39 |
| Operating cash flow | -$18.55M | -$15.95M | -$383.6K | -$2.99M |
| Free cash flow | -$18.59M | -$15.98M | n/a | n/a |
| Cash & equivalents | $5.19M | $15.96M | $69.6K | $681.5K |
| Total assets | $18.13M | $17.74M | $274.6K | $21.06M |
| Total liabilities | $35.72M | $3.14M | $6.56M | $7.76M |
| Shareholders' equity | -$17.59M | $14.86M | -$6.28M | $11.11M |
| Return on year-end equity | n/a | -111.7% | n/a | -71.2% |
| Shares outstanding | 10.85M | 8.83M | 39.37M | 25.05M |
Revenue, most recent five fiscal years
| Fiscal year | Clene Inc. | Lisata Therapeutics, Inc. | Regen BioPharma Inc | Abvc Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $200.0K Ended 2025-12-31 | $170.0K Ended 2025-12-31 | $236.6K Ended 2025-09-30 | $296.0K Ended 2025-12-31 |
| 1 year earlier | $342.0K Ended 2024-12-31 | $1.00M Ended 2024-12-31 | $236.6K Ended 2024-09-30 | $509.6K Ended 2024-12-31 |
| 2 years earlier | $654.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $236.6K Ended 2023-09-30 | n/a |
| 3 years earlier | $473.0K Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $723.0K Ended 2021-12-31 | n/a | n/a | n/a |